Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis--an open clinical trial.
スポンサーリンク
概要
- 論文の詳細を見る
BACKGROUND: Pentosan polysulfate sodium (pentosan) is a semi-synthetic drug manufactured from beech-wood hemicellulose by sulfate esterification of the xylopyranose hydroxyl groups. From in vitro and animal model studies, pentosan has been proposed as a disease modifying osteoarthritis drug (DMOAD). The objective of this study was to assess the efficacy, safety, and patient satisfaction in patients with mild radiographic knee osteoarthritis (OA) findings and OA-associated symptoms and signs. METHODS: Twenty patients were assessed clinically at Nagasaki University Hospital. The radiographic indications of OA were grade 1 to 3 using the Kellgren-Lawrence Grading System (K/L grade). Pentosan used in this study was manufactured and supplied in sterile injectable vials (100 mg/ml) by bene GmbH, Munich, Germany. The study was a single-center, open-label trial. Treatment consisted of 6 weekly subcutaneous injections (sc) of pentosan (2 mg/kg). Patients were clinically assessed at entry and 1 to 8, 11, 15, 24 & 52 weeks post treatment. The results were analyzed using one way ANOVA and Dunnett's method. RESULTS: Hydrarthroses were reduced quickly in all cases. The clinical assessments, i.e., knee flexion, pain while walking, pain after climbing up and down stairs, etc, were improved significantly and these clinical improvements continued for almost one year. The dose used in this study affected the blood coagulation test, but was within safe levels. Slightly abnormal findings were noted in serum triglycerides. CONCLUSIONS: Pentosan treatment in twenty patients with mild knee OA seemed to provide improvements in clinical assessments and C2C level of cartilage metabolism.
- 2010-03-28
論文 | ランダム
- 国内学術雑誌における著作権の取り扱い調査 著作権規定のひな型と『情報管理』誌におけるケーススタディ
- 1314 地下街探査ロボットを用いた神戸市地下街での実証実験(GS-15 ロボット(1))
- 老化と寿命決定因子 インスリン・IGF-1による老化・寿命調節機構 (特集 アンチエイジング医学--基礎・臨床研究の進歩) -- (基礎研究の進歩)
- 18か月児の社会能力に関連する要因に関する追跡研究
- グルコキナーゼ活性化と膵β細胞増殖 (特集 糖尿病治療のUp-to-Date) -- (膵β細胞を増やす)